Compounding Pharmacies vs. Big Pharma: The Battle for Dominance in the Growing GLP-1 Market
October 22, 2024
The competitive landscape for GLP-1 receptor agonists, particularly in obesity and diabetes treatment, is undergoing a transformation. Novo Nordisk and Eli Lilly, long-time leaders in this space, face challenges not only from emerging
